ULTRASOUND MEDIATED MEMBRANE PERMEABILITY-DRUG DELIVERY

Information

  • Research Project
  • 2790432
  • ApplicationId
    2790432
  • Core Project Number
    R43HL062024
  • Full Project Number
    1R43HL062024-01
  • Serial Number
    62024
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/15/1999 - 26 years ago
  • Project End Date
    7/14/2000 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    1/15/1999 - 26 years ago
  • Budget End Date
    7/14/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    1/14/1999 - 26 years ago
Organizations

ULTRASOUND MEDIATED MEMBRANE PERMEABILITY-DRUG DELIVERY

The overall goal of this project is to demonstrate the feasibility of using ultrasound to temporarily make vascular tissue more permeable and thereby deliver drug to the cells in the vessel wall (e.g. smooth muscle cells). EKOS has developed an ultrasound-catheter device for the transmural delivery of drugs and we are seeking to understand the mechanisms by which ultrasound can make tissue more permeable and thereby enhance transport of drugs and genes into target tissues and inside of cells. We propose the use of ultrasound to transiently disrupt cell membranes for delivery of drugs, proteins, and DNA. This non-chemical, non-viral, and minimally-invasive approach could provide a safe means for targeted cell uptake in the treatment of restenosis and other cardiovascular diseases. Despite compelling initial experiments, ultrasound-mediated cell permeabilization has been insufficiently characterized to rationally design protocols for applications. understanding the effects of ultrasound parameters on cells and reproducibly achieving those effects at different times and in different patients is essential to developing a clinical product. The specific aims are: 1. Determine the effect of acoustic parameters on molecular uptake and cell viability 2. Characterize the size and lifetime of membrane disruptions 3. Identify acoustic signals that correlate with membrane disruption threshold PROPOSED COMMERCIAL APPLICATION: Our product will be an ultrasound catheter device that actively delivers drug into the artery wall for the treatment of restenosis.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    EKOS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    BOTHELL
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98011
  • Organization District
    UNITED STATES